Table 4 Pharmacokinetics of artemether–lumefantrine during pregnancy
Publication | Description | Median (range) Day 7 lumefantrine concentration | Median (range) lumefantrine Cmax | Lumefantrine exposure | Artemether exposure (AUC0→8h) |
|---|---|---|---|---|---|
McGready et al., 2006[21] | Pharmacokinetic study of AL in pregnancy using venous plasma samples (n = 13). Results compared with a previous report in non-pregnant adults (n = 17) | 384 ng/ml (62–835)* | 7340 ng/ml (1,590–15,670)* | Pregnant: 237 μg/ml.h (90% predicted range 75–576)†, Non-pregnant: 251 μg/ml.h (90% predicted range 79–616)† | Pregnant, median (90% range): 66.4 ng/ml.h (10.5–264.8), Non-pregnant, mean (SD): 211 ng/ml.h (109) |
Tarning et al., 2009[37] | Pharmacokinetic study of AL in pregnancy using capillary plasma samples (n = 103) | Capillary plasma: 391 ng/ml (126–1,600), venous plasma (approx): 310 ng/ml (94–1,364) | AUC0→∞, median (range): 472 μg/ml.h (119–1,261) | ||
Piola et al., 2010[25] | Open-label, randomized study of AL vs. Q in the 2nd and 3rd trimesters, with pharmacokinetic analysis of venous plasma samples (n = 97) | 481 ng/ml (15–3,246) |